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Abstract 
As cannabis use is more frequent in psychosis patients than the general population and is 
known to be a risk factor for psychosis, the question arises whether cannabis contributes to 
recently detected brain volume reductions in schizophrenic psychoses. This study is the first to 
investigate how cannabis use is related to cingulum volume, a brain region involved in the 
pathogenesis of schizophrenia, in a sample of both at risk mental state (ARMS) and first episode 
psychosis (FEP) subjects. A cross-sectional MRI study of manually traced cingulum in 23 FEP 
and 37 ARMS subjects was performed. Cannabis use was assessed with the Basel Interview for 
Psychosis. By using repeated measures ANCOVAs, we investigated whether current cannabis 
use is associated with cingulum volume, correcting for age, gender, alcohol consumption, whole 
brain volume and antipsychotic medication. There was a significant three way interaction 
between region (anterior/posterior cingulum), hemisphere (left/right cingulum) and cannabis use 
(yes/no) (F (1, 51) = 5.62, Partial η2 = 0.10, p = 0.022). Post hoc analyses revealed that this was 
due to a significant negative effect of cannabis use (F (1, 51) = 8.96, Partial η2 = 0.15, p = 0.004) 
on volume of the posterior cingulum which was independent of the hemisphere and diagnostic 
group and all other covariates we controlled for. In the anterior cingulum, we found a significant 
negative effect only on left hemisphere (F (1, 51) = 7.02, Partial η2 = 0.12, p = 0.011), which was 
again independent of diagnostic group.  
Overall, we found negative associations of current cannabis use with grey matter volume of 
cingulate cortex, a region rich in CB1 receptors. As this finding has not been consistently found 
in healthy controls, this might suggest that both ARMS and FEP subjects might be particularly 
sensitive to exogenous activation of these receptors.  
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1. Introduction 
The cingulum is a functionally heterogeneous region, involved in a range of behavioural domains 
(Vogt et al., 1992). It represents a key structure within the limbic system and is composed of 
several areas which differ in respect to structure and function: the different sub divisions play an 
important role in emotional, cognitive, attentional, nociceptive, and motoric processing (Bush et 
al., 2000; Vogt et al., 1992). The anterior cingulate cortex (ACC) represents a central component 
of those subdivisions that control affective and cognitive functions. The central task of this brain 
region is the modulation of inner emotional reactions. The ACC has anatomical connections to 
the dorsolateral prefrontal cortex, motoric areas and the thalamus, depending on the specialised 
subdivision. It is an essential component of social cognition and visualizing and is mainly 
activated by emotional stimuli (Bush et al., 2000; Kopelman et al., 2005). The posterior cingulate 
cortex (PCC) is activated both through emotional and non-emotional stimuli and plays an 
important role in memory access, visual span and spatial orientation (Vogt et al., 1992; Vogt and 
Laureys, 2005; Vogt et al., 2006). 
Studies of individuals with genetic or clinical risk for psychosis have indicated that the cingulum 
might be involved in the pathogenesis of schizophrenia (for review, see Borgwardt et al., 2009; 
Fusar-Poli et al., 2008; Fusar-Poli et al., 2011; Smieskova et al., 2010). A recent study from our 
group reported that At Risk Mental State (ARMS) (Yung et al., 2005) subjects had significantly 
reduced left caudal ACC volume compared to healthy controls and within ARMS, those who later 
made the transition to psychosis (ARMS-T), showed significantly reduced whole right cingulate 
cortex, right subgenual cingulate cortex, and right PCC compared to ARMS who did not make 
the transition to psychosis (ARMS-NT) (Röthlisberger et al., 2012). 
Cannabis use and abuse occurs much more frequently in psychosis patients than in the general 
population (Koskinen et al., 2010) and is suspected to be a risk factor for psychosis (Drewe et 
al., 2004; Moore et al., 2007). Neurobiological models for this association postulate that delta-9-
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tetrahydrocannabinol (THC, the main psychoactive component of cannabis) causes 
dopaminergic imbalances by increasing the dopaminergic tone in striatal regions of the brain via 
activation of cannabinoid 1 (CB1) receptors and decreasing dopamine levels in prefrontal 
regions of the brain (Kuepper et al., 2010). However, most evidence supporting this stems from 
animal research (Kuepper et al., 2010) and has not been empirically investigated in humans. 
Nevertheless, there is clear evidence that there are associations between schizophrenia and 
alterations of dopamine (for review, see Howes and Kapur, 2009) as well as between 
schizophrenia and brain structural alterations (for review, see Steen et al., 2006). 
Another neurobiological explanation for the cannabis-psychosis association could be that 
cannabis contributes to abnormalities in brain structure and therefore the development of 
psychotic symptoms. Although studies investigating how cannabis affects brain structure of 
healthy individuals have produced inconsistent results, the most consistent brain volume 
abnormalities associated with cannabis use in healthy controls were found in medial temporal 
regions (for review, see Lorenzetti et al., 2010; Martin-Santos et al., 2010). It has been reported 
that in ACC, cannabis may affect the integrity of white matter fiber tracts (Gruber and Yurgelun-
Todd, 2005). Functional MRI studies found that acute administration of THC or marijuana 
increases resting activity and activation of the ACC during cognitive tasks (Martin-Santos et al., 
2010). There is only one structural MRI study with healthy controls that took into account the 
effects of cannabis on the cingulum volume. Specifically, Cousijin et al. (2012) reported negative 
associations between amygdala/ hippocampus grey matter volume and amount of cannabis use 
but no associations of cannabis with ACC and striatum in a voxel based morphometry study 
(Cousijn et al., 2012).  
In contrast to humans, animal studies have demonstrated that THC induced dose-dependent 
neurotoxic changes in brain regions rich in CB1 receptors (Downer et al., 2001; Landfield et al., 
1988; Whitaker-Azmitia et al., 2000). However, this could also be due to the fact that in animal 
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studies, the THC doses administered were high and THC was often not mixed with other 
cannabinoids. There are also studies which reported neuroprotective effects of cannabinoids in 
animals (e.g. Sagredo et al., 2011). 
We have recently reviewed studies comparing brain volumes of cannabis using patients with 
psychosis with those of non-using psychosis patients and healthy controls (Rapp et al., 2012).  
The systematic review demonstrated that cannabis use is associated with smaller volume of 
global and specific brain structures, particularly in CB1 receptor rich brain regions, such as the 
cingulate cortex (Bangalore et al., 2008; Szeszko et al., 2007), prefrontal cortices (James et al., 
2011; Rais et al., 2010) and the cerebellum (James et al., 2011; Solowij et al., 2011). 
Furthermore, the associations between brain structural volume reductions and cannabis 
consumption were more pronounced in psychosis patients and individuals at genetic risk for 
psychosis than in healthy controls, suggesting that these groups might be particularly vulnerable 
to brain volume loss due to cannabis exposure. Our literature review also revealed that, to date, 
only one study (Stone et al., 2011) investigated the effect of cannabis on brain structure in 
ARMS. By analysing the interaction between the two diagnostic groups (ARMS / first episode 
psychosis (FEP)) and cannabis use, conclusions can be drawn as to whether cannabis use is 
associated with brain structure in a disease stage-dependent manner. To this end, associations 
between cannabis consumption and cingulum volume in both ARMS and FEP samples that 
were obtained within the same study, were investigated. We hypothesized that: 
1. cannabis use is associated with lower grey matter volumes in the cingulate cortex in both 
diagnostic groups. 
2. these associations are more pronounced in FEP than in ARMS subjects. 
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2. Methods 
2.1. Setting and recruitment 
This study was part of the Basel FePsy (Früherkennung von Psychosen) study, which aims to 
improve the early detection of psychosis. The FePsy study has been described in detail 
elsewhere (Riecher-Rössler et al., 2007; Riecher-Rössler et al., 2009). Subjects were recruited 
into the study via a specialised outpatient clinic at the Psychiatric Outpatient Department at the 
University Hospital Basel. This clinic was set up specifically to identify, assess, and follow up 
individuals in the early stages of psychosis. The study was approved by the Ethics Committee of 
Basel, Switzerland (EKBB), and written informed consent was obtained from each of the 
participants. 
 
2.2. Screening procedure 
For screening, the Basel Screening Instrument for Psychosis (BSIP) was used (Riecher-Rössler 
et al., 2008). Individuals were assessed and identified as ARMS, FEP, or “not at risk for 
psychosis” (i. e. other psychiatric diseases) subjects.  
 
2.3. Participants 
In this study, we present data of 60 patients from the Basel FePsy study who agreed to 
participate in the imaging arm of the study. 23 of the patients were identified as FEP and 37 as 
ARMS subjects. Data of this study are overlapping with our previous studies (Bühlmann et al., 
2010; Röthlisberger et al., 2012; Walter et al., 2012) (overlapping n = 60). 
 
2.4. Cannabis, alcohol and other drug use 
Cannabis, alcohol and other drug use was determined both for ARMS and FEP at study 
inclusion by using the Basel Interview for Psychosis (BIP) (Riecher-Rössler et al., in 
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preparation), a structured and specifically developed interview for the assessment of psychosis 
development, which is much more detailed than the BSIP. The BIP contains two items assessing 
the frequency of past and present cannabis/alcohol/other drug consumption. Past drug 
consumption refers to lifetime consumption, present consumption to the frequency participants 
reported to usually use cannabis during assessments. Frequency of substance use is assessed 
by these items on a five-point ordinal scale using the following response categories: daily, 
several times a week, several times a month, less than several times a month, and not at all. For 
the present analyses, only current substance use was considered. A dichotomous variable of 
cannabis use was created differentiating between current cannabis users (= daily, several times 
a week, several times a month and less than several times a month) and non-users (= no use at 
all). 
In 60% of the included patients, cannabis use was additionally assessed by urine toxicology 
screens. Urine tests were considered positive when THC-COOH was present in the urine in a 
concentration of at least 10µg/l, in order to infer a detection window of ≈1 month. Although urine 
tests were only available in a subset of our sample, the agreement between urine tests and the 
questionnaire item on current use was excellent. That is, all patients with cannabis-positive urine 
had responded to the questionnaire item measuring current cannabis use with a frequency of at 
least rarely and all patients with cannabis-negative urine had responded with a frequency less 
than several times per month. Hence, relying only on information of the BIP in those patients 
who did not have urine toxicology screens was considered well justified. 
 
2.5. Structural MRI 
2.5.1. Image acquisition 
Subjects were scanned using a Siemens (Erlangen, Germany) Magnetom Vision 1.5 T scanner 
at the University Hospital Basel. Head movement was minimized by foam padding and velcro 
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straps across the forehead and chin. A three-dimensional volumetric spoiled gradient recalled 
echo sequence generated 176 contiguous, 1 mm thick sagittal slices. Imaging parameters were: 
time-to-echo, 4 msec; time-to-repetition, 9.7 msec; flip angle, 12; matrix size, 200 x 256; field of 
view, 25.6 x 25.6 cm matrix; voxel dimensions, 1.28 x 1 x 1 mm.  
 
2.5.2. Manual segmentation of cingulum and whole brain volume 
Original DICOM data were converted to Analyze 7.5 format in axial direction coded to ensure 
blindness of the investigator and patients' confidentiality and finally imported into the image-
analysis software AMIRA (Kappos et al., 2006). Anatomical definition of the ACC and PCC were 
made by using Talairach CoPlanar Stereotaxic Atlas (Talairach et al., 1993). The paracingulate 
gyrus was considered to be a part of ACC, which is in accordance with several other studies 
(e.g. Koo et al., 2008). The cingulum volume was traced strictly following the protocol of 
Röthlisberger et al. (2012) (see online supplementary document 1). In the present study, we 
focused upon the anterior (left/right) and the posterior (left/right) cingulum. 
The whole brain volume (WBV) was measured to correct for differences in head size as 
previously described (Borgwardt, McGuire et al. 2007; Borgwardt, Riecher-Rössler et al. 2007; 
Haller, Borgwardt et al. 2009). 
 
2.5.2.1. Intra-rater reliability / inter-rater reliability 
To assess an intra-rater reliability, a manual segmentation in ten consecutive cases was 
accomplished by the same person (MR) within two weeks. The intra-rater reliability was as 
follows: ICCtotal left = 0.95, ICCtotal right = 0.95, ICCant left = 0.98, ICCant right = 0.98, ICCpost left = 0.81, 
ICCpost right = 0.89.  
In order to calculate an inter-rater reliability, a second rater (AW) manually traced the cingulum 
of ten randomly selected cases. The inter-rater reliability was as follows: ICCtotal left = 0.96, ICCtotal 
right = 0.97, ICCant left = 0.97, ICCant right = 0.98, ICCpost left = 0.95, ICCpost right = 0.94. 
 8 
 
The researchers (MR and AW) who traced the cingulate volumes were blind to the group status 
at any time of the study. They were trained and supervised by a specialised neuroradiologist 
according to the procedure described in online supplementary document 1. Once the gray 
matter of the cingulate cortex had been traced, volumes (in mm3) were calculated by computing 
the number of voxels from each traced image. 
 
2.6. Statistical analysis 
All analyses were performed using the Statistical Package for the Social Sciences (SPSS) 
version 19. Two tailed t-tests for the continuous and χ2 tests for the categorical variables were 
used in order to compare groups for demographic and clinical data (p<0.05).  
A repeated measures ANCOVA model was calculated including grey matter volume as 
dependent variable, hemisphere (left/right) and region (anterior/posterior cingulum) as within 
subjects variables and group (ARMS/FEP) and cannabis use (yes/no) as between subject 
variables. Age, sex, medication, whole brain volume and alcohol use were entered as covariates 
(p<0.05). 
3. Results 
3.1. Sample characteristics  
The socio-demographic characteristics of the sample are presented in Table 1. There were no 
significant differences between ARMS and FEP subjects with regard to age, gender, education, 
alcohol use, and whole brain volume. FEP subjects had a significantly higher BPRS total score (t 
(56) = -4.33, p < 0.001) and showed a statistical trend toward a higher SANS total score (t (57) = 
-1.71, p = 0.09) than ARMS subjects. A large proportion of FEP subjects were scanned within 1-
3 days of first contact. Therefore, most of the FEP subjects (14/23) were also antipsychotic-
 9 
 
naïve. The remaining nine participants were prescribed second generation antipsychotic 
medications (six of them for less than one month; three participants received risperidone, six 
olanzapine).Thirty-three out of 37 ARMS subjects had never received antipsychotic medication. 
Four ARMS subjects had received low doses of second generation antipsychotic medication 
during no more than three weeks for behavioural control by the referring psychiatrist or general 
practitioner prior to study inclusion. Three of these participants had received olanzapine and one 
risperidone. 
 
3.2. Cannabis use 
Of the ARMS subjects, 63.3% reported to currently use cannabis with a frequency ranging from 
daily to less than monthly. From the FEP subjects, 75% were current cannabis users. ARMS and 
FEP subjects did not differ with regards to frequency of cannabis use. Current cannabis users 
and non-users did not differ with regard to age, gender, medication, alcohol, whole brain volume, 
BPRS total, and SANS total scores. However, cannabis users had a significantly lower 
education (t (58) = 3.04, p = 0.004) than non-users. 
 
Insert Table 1 here 
 
3.3. Brain volumes in cannabis users and non-users 
Figure 1 shows the means ± one standard deviations of cingulum volumes for cannabis users 
and non-users in the two diagnostic groups (ARMS/FEP).  
Insert Figure 1 here 
 
The within subject contrasts of the ANCOVA including hemisphere (left/right) and region 
(ACC/PCC) as within subjects factors and group (ARMS/FEP) and cannabis use (yes/no) as 
 10 
 
between subject factors with age, sex, medication, whole brain volume and alcohol use as 
covariates revealed a significant three way interaction between region, hemisphere and 
cannabis use (F (1, 51) = 5.62, Partial η2 = 0.10, p = 0.022). To further examine this effect, each 
region was analysed in separate ANCOVA models using hemisphere as within subject factor, 
group and cannabis use as between subject factors and age, sex, medication, whole brain 
volumes, and alcohol use as covariates (Table 2). The results revealed that there was a 
significant negative effect of cannabis use on PCC (F (1, 51) = 8.96, Partial η2 = 0.15, p = 0.004) 
which was independent of diagnostic group and hemisphere and a statistical trend for an 
interaction effect between hemisphere and cannabis use (F (1, 51) = 3.95, Partial η2 = 0.07, p = 
0.052) on the ACC which was independent of group. Two further post hoc univariate ANCOVAs 
for each of the two hemispheres revealed a significant effect of cannabis use only on the left 
ACC (F (1, 51) = 7.02, Partial η2 = 0.12, p = 0.011). 
When the analyses were repeated by excluding individuals using other illicit drugs (i.e., one 
using MDMA and one using psychedelics), the results did not change. 
 
 
Insert Table 2 here 
 
4. Discussion  
This study investigated whether cannabis use is associated with cingulate cortex volume in early 
stages of psychosis. As the first study in this field, we included both an ARMS and FEP sample. 
We found a significant negative effect of cannabis use on PCC volumes which was independent 
of the hemisphere and diagnostic group and all other covariates we controlled for. In the ACC, 
we found a significant negative effect only on left hemisphere, which was again independent of 
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diagnostic group. The findings remained the same when individuals using other illicit drugs were 
excluded. 
 
4.1. Prevalence of cannabis use  
63.3% of our ARMS and 75% of the FEP subjects reported to currently use cannabis (Table 1). 
According to a Swiss health survey from the year 2004, 13.3% of all 13-29 year aged individuals 
stated to currently use cannabis (Arbeitsgruppe Cannabismonitoring, 2005). Therefore, the 
prevalence of cannabis use in our FEP/ARMS sample seems to be much higher than in the 
general population which is in line with other studies (Drewe et al., 2004; Koskinen et al., 2010). 
Cannabis users in our sample had significantly less educational years than non-users. Similarly, 
other studies investigating non-help seeking subjects reported that cannabis use is associated 
with reduced educational achievement (Fergusson and Boden, 2008; Patton et al., 2007), 
increased welfare dependence (Schmidt et al., 1998) and reduced income (Degenhardt et al., 
2007), however it is often not clear whether cannabis consumption actually preceded this 
(Barnwell et al., 2006). 
 
4.2. Integration of other studies on brain structure in cannabis users with psychosis 
Our reported associations of cannabis use with reduced brain volume are in line with previous 
MRI studies: within a recent review from our group (Rapp et al., 2012) in which 15 in vivo 
structural MRI studies were included, 11 found that cannabis use was associated with a 
decrease in global or specific brain structures in psychosis patients (Bangalore et al., 2008; 
Habets et al., 2011; Ho et al., 2011; James et al., 2011; Rais et al., 2008; Rais et al., 2010; 
Solowij et al., 2011; Szeszko et al., 2007) and in individuals at clinical/genetic risk for psychosis 
(Habets et al., 2011; Stone et al., 2011; Welch et al., 2011a; Welch et al., 2011b). The cingulate 
cortex was specifically investigated in two studies (Bangalore et al., 2008; Szeszko et al., 2007). 
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Szeszko et al. (2007) compared frontal gyrus, anterior cingulate gyrus, and orbital frontal lobe in 
20 FEP subjects with an additional diagnosis of cannabis abuse or dependence with 31 FEP 
subjects with no cannabis use and with healthy volunteers. They reported that patients 
experiencing a first episode of schizophrenia who have a history of cannabis use have less 
whole anterior and specifically left anterior cingulate cortex grey matter compared with similar 
patients who do not use cannabis and with healthy volunteers. In a similar study, Bangalore et 
al. (2008) investigated the dorsolateral prefrontal cortex, hippocampus, posterior cingulate, and 
cerebellum in 57 FEP subjects both with and without comorbid cannabis use. A decrease in grey 
matter density in the right posterior cingulate cortex (PCC) was found in cannabis using subjects 
when compared with non-using subjects and healthy controls.  
 
4.3. The cingulate cortex, its involvement in psychosis and vulnerability to the effects of 
cannabis use 
The findings from Bangalore et al. (2008) and Szeszko et al. (2007) and our present results 
suggest that the cingulate cortex might be a brain region specifically vulnerable for the influence 
of cannabis use in psychosis. As indicated by recent studies, a decrease of volume in this brain 
region might be a specific risk factor for transition to psychosis. More precisely, anterior subunits 
have been shown to be affected in early stages during the prodrome, posterior subunits in later 
stages when it comes to a transition to psychosis (Borgwardt et al., 2008; Fornito et al., 2008; 
Röthlisberger et al., 2012). 
The cingulum is a brain area rich in CB1 receptors (Eggan and Lewis, 2007), which are 
responsible for the psychotropic actions of cannabis. CB1 receptors deliver the effects of both 
endogenous and exogenous (such as THC) cannabinoids from cannabis sativa in the central 
nervous system and are therefore part of the endocannabinoid system (Kuepper et al., 2010). 
Post mortem studies (Dean et al., 2001; Eggan et al., 2008) revealed that schizophrenia is 
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associated with alterations in the endocannabinoid system. Zavitsanou et al. (2004) examined 
post-mortem radioligand binding of [3H]SR141716A, an antagonist that specifically targets CB1 
receptors of the endogenous cannabinoid system, on ACC sections using quantitative 
autoradiography. They found a significant 64% increase in [3H]SR141716A specific binding to 
CB1 receptors in the schizophrenia group compared to a control group. Dean et al. (2001) 
additionally showed that acute cannabis effects in both patients with schizophrenia and healthy 
controls is associated with change in density of CB1 in tissue. Therefore, a plausible 
consequence of chronic cannabis use might be that structures rich in CB1 receptors, such as the 
subunits of the cingulate cortex, decrease in volume and therefore might accelerate the 
progression of psychosis. As described before, the left anterior subunit might be a specific 
marker for ARMS, and the posterior subunit a specific marker for transition to psychosis (ARMS-
T, FEP) (Röthlisberger et al., 2012).This could be a consequence of CB1 receptors deferring 
from protecting the brain against excitotoxic influence (Rais et al., 2010). CB1 receptors 
activated by the endogenous cannabinoids protect the brain from excitotoxic events (Kim et al., 
2006), such as N-methyl-Daspartate (NMDA) toxicity (Kim et al., 2006) or kainic acid injection 
(Marsicano et al., 2003). This physiological process of CB1 receptors playing a neuroprotective 
role against excitotoxic events might be disrupted by exogenous cannabinoids (Egerton et al., 
2006).   
A possible influence of cannabis on ACC also seems plausible as it plays an important role in 
normal cognition and attention (Bush et al., 2000). Long term cannabis use has been reported to 
impair those functions (e.g. Crean et al., 2011; Solowij et al., 2002) which also resemble core 
negative symptoms in psychosis, although this effect was not consistently confirmed in the 
literature (e.g. Fried et al., 2005; Grant et al., 2003). Additionally, changes in dopaminergic, 
serotonergic, glutamatergic and GABAergic systems were reported in ACC in schizophrenia 
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which are all interconnected with the cannabinoid system (Zavitsanou and Huang, 2002; 
Zavitsanou et al., 2002). 
In our study, we specifically found strong associations of cannabis use with PCC, which was 
similarly reported by Bangalore et al. (2008). It has been shown that poor outcome in 
schizophrenia is associated with smaller PCC (Mitelman et al., 2005), and reductions in the 
volume of bilateral PCC seem to be predictive for transition to psychosis in ARMS subjects 
(Pantelis et al., 2003; Röthlisberger et al., 2012).  
4.4. Brain changes associated with cannabis use in individuals at risk for psychosis 
To date, studies of subjects at high genetic (Habets et al., 2011; Welch et al., 2011a; Welch et 
al., 2011b) or clinical (Stone et al., 2011) risk for psychosis found that cannabis use was 
associated with altered global and specific grey matter volume, and three of them also reported 
that this effect was stronger in individuals at risk for psychosis than in healthy controls, 
suggesting that individuals at risk for psychosis may be more vulnerable for the neurotoxic effect 
of cannabis than healthy individuals. Welch et al. (2011a) who investigated the association 
between substance misuse and brain abnormality not only found that use of cannabis by people 
at genetic high risk for schizophrenia is associated with brain abnormalities but also that 
individuals at risk for psychosis consuming cannabis had an elevated rate of developing 
schizophrenia than those subjects without cannabis use.  
These previous findings are in line with the present data which showed that cannabis using 
ARMS subjects had smaller cingulum volume than non-users.  
We a priori expected an interaction between group status (ARMS/FEP) and cannabis use such 
that there is more grey matter reduction in consequence of cannabis use in FEP than in ARMS 
subjects. However, this hypothesis could not be confirmed within our study, suggesting that the 
brain in psychosis is affected by cannabis use regardless of the disease stage.  
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4.5. Limitations 
The present study has several limitations: first, we could not compare the findings with a 
cannabis using healthy control sample. Hence, we were unable to analyse whether cannabis 
has a differential effect on brain structure in psychosis patients compared to healthy individuals. 
Second, we only assessed the frequency of current cannabis use but not a cumulative dose of 
THC content. Therefore, associations between cumulative dose of cannabis and cingulum 
volume could not be examined. Finally, given the cross-sectional nature of this study, the 
association between cannabis use and cingulum volume cannot be interpreted causally.. 
 
4.6. Conclusions 
Our hypotheses could be partly confirmed: there were strong associations of cannabis use with 
the cingulate cortex, a region identified as being rich in CB1 receptors. However, this effect was 
not different for FEP and ARMS subjects. This might suggest that both ARMS as well as FEP 
subjects could be particularly sensitive to exogenous activation of these specific receptors.  
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Figure Legend 
 
Figure 1: Means ± one standard deviation (vertical line) of cingulum volumes for cannabis users 
and non-users in the two diagnostic groups (ARMS/FEP)  
 
 
 
 
 
 
 
 
Table 1: Socio-demographic characteristics§ of ARMS and FEP 
 ARMS (n=37) FEP (n=23) Significance value 
Men n = 22 (36.7%) n = 17 (28.3%) χ2 (1) = 1.3; p = 0.25 
Women n = 15 (25%) n = 6 (10%)  
Cannabis Use      
No use n = 22 (36.7%) n = 15 (25%) χ2 (4) = 0.48; p = 0.98 
More seldom 
than monthly n = 3 (5%) n = 1 (1.7%)  
More than 
monthly n = 2 (3.3%) n = 1 (1.7%)  
More than 
weekly n = 4 (6.7%) n = 2 (3.3%)  
Daily n = 6 (10%) n = 4 (6.7%)  
Alcohol Use      
No use n = 19 (31.7%) n = 12 (20%) χ2 (4) = 7.20; p = 0.13 
More seldom 
than monthly n = 9 (15%) n = 4 (6.7)  
More than 
monthly n = 3 (5%) n = 3 (5%)  
More than 
weekly n = 6 (10%) n = 1 (1.7%)  
Daily n = 0 (0%) n = 3 (5%)  
Antipsychotic 
medication n = 4 (10.8%) n = 9 (39.1%) χ
2 (2) = 14.2; p = 0.001 
Age 25.15 (6.32) 27.27 (6.47) t (58) = -1.25; p = 0.22 
Education (in 
years) 10.81 (2.79) 10.0 (3.22) t (58) = 1.03; p = 0.30 
BPRS total 39.35 (8.89) 52.52 (14.36) t (56) = -4.33; p  = 0.00 
SANS total 27.0 (17.87) 35.7 (20.49) t (57) = -1.71; p = 0.09 
Whole brain 
volume [means 
in mm3] 
1286748 (113674) 1307844 (115520) t (58) = -.69; p = 0.49 
Anterior 
cingulum left 
4822 (1274) 
Cannabis users: 4263 (1092) 
Non-users: 5204 (1269) 
5095 (1743)  
Cannabis users: 4730 (1705) 
Non-users: 5290 (1788) 
t (58) = -0.70; p = 0.45 
Anterior 
cingulum right 
4976 (1647) 
Cannabis users: 5252  (1720) 
Non-users: 4789 (1607) 
4668 (1054) 
Cannabis users: 4688 (1301) 
Non-users: 4657 (947) 
t (58) = 0.80; p = 0.43 
Posterior 
cingulum left 
4315 (642) 
Cannabis users: 4142  (463) 
4256 (894) 
Cannabis users: 3955 (581) 
t (58) = 0.29; p = 0.77 
Non-users: 4433 (726) Non-users: 4416 (1004) 
Posterior 
cingulum right 
4327 (939) 
Cannabis users: 4137 (1159) 
Non-users: 4457 (757) 
4425 (745) 
Cannabis users: 4185 (663) 
Non-users: 4554 (775) 
t (58) = -0.43; p = 0.67 
§
 Unless indicated otherwise values are given as means with SD in parentheses. 
 
Table 2: Repeated measures ANCOVA integrating hemisphere (left/right) and region 
(anterior/posterior cingulum) as within subjects variables and group (ARMS/FEP) and 
cannabis use (yes/no) as between subjects variables. Age, sex, medication, whole brain 
volume and alcohol use as covariates. 
 
 Anterior Cingulum Posterior Cingulum 
 Partial η2 F (df) p Partial η2 F (df) p 
Age 0.00 0.08 (1, 51) 0.77 0.10 5.61 (1, 51) 0.02* 
Sex 0.00 0.01 (1, 51) 0.91 0.07 3.62 (1, 51) 0.06 
Whole brain volume 0.00 0.01 (1, 51) 0.91 0.04 1.94 (1, 51) 0.17 
Alcohol use 0.00 0.14 (1, 51) 0.71 0.05 2.50 (1, 51) 0.12 
Medication 0.01 0.37 (1, 51) 0.55 0.03 1.56 (1, 51) 0.22 
Group 0.00 0.13 (1, 51) 0.72 0.01 0.67 (1, 51) 0.41 
Cannabis use 0.02 0.80 (1, 51) 0.37 0.15 8.96 (1, 51) 0.00* 
Hemisphere 0.00 0.02 (1, 51) 0.90 0.13 7.49 (1, 51) 0.01* 
Group * cannabis use 0.00 0.03 (1, 51) 0.85 0.01 0.43 (1, 51) 0.52 
Hemisphere * age 0.02 0.85 (1, 51) 0.36 0.01 0.32 (1, 51) 0.58 
Hemisphere * sex 0.01 0.62 (1, 51) 0.43 0.01 0.60 (1, 51) 0.44 
Hemisphere * whole brain 0.01 0.40 (1, 51) 0.53 0.11 6.55 (1, 51) 0.01* 
Hemisphere * alcohol use 0.01 0.56 (1, 51) 0.45 0.04 2.21 (1, 51) 0.14 
Hemisphere * medication 0.01 0.25 (1, 51) 0.62 0.01 0.14 (1, 51) 0.71 
Hemisphere * group 0.01 0.31 (1, 51) 0.58 0.01 0.28 (1, 51) 0.60 
Hemisphere * cannabis use 0.07 3.50 (1, 51) 0.05 0.00 0.00 (1, 51) 0.97 
Hemisphere * group * 
cannabis use 
0.01 0.27 (1, 51) 0.60 0.00 0.03 (1, 51) 0.86 
* p < 0.05 
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Online supplementary document 1: Cingulum tracing protocol (according to 
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We focused upon anterior (ACC) and posterior cingulate cortex (PCC) both right and left as 
our Region-of-interest (ROI). ACC underwent a further segmentation in functional 
subdivisions, particularly rostral anterior (RACC), caudal anterior (CACC) and subgenual 
cingulate cortex (SCC), both right and left. Cingulate volume was calculated by summing up 
all the marked voxels, using the software for medical imaging amira™, which displays all 
three planes simultaneously. To reach an equal tracing of those ROI’s, for each and every 
patient the same approach was used including clearly defined landmarks and lines. Tracing 
was made individually with a mouse-driven cursor for each sagittal and coronal plane. 
Preceding anatomical definition of the ACC and PCC was made by using Talairach Co-
Planar Stereotaxic Atlas (Talairach et al., 1993). Before tracing began, several reference 
lines needed to be drawn on the most medial sagittal slice of each hemisphere. Two 
landmarks where used to reach a standard segmentation (Figure 1): 
 
CA-CP-Line:  this line passes through the superior edge of the anterior commissure and the 
inferior edge of the posterior commissure. It follows a path essentially parallel to the 
hypothalamic sulcus, dividing the thalamic from the sub-thalamic region. This line defines the 
horizontal plane (Talairach et al., 1993). 
 
VCA-Line:  this line is a vertical transversing the posterior margin of the anterior 
commissure.  
This line is the basis for the vertical plane (Talairach et al., 1993). 
 
  
Figure 1 
 
By setting the VCA-line with the grid-function offered by the medical imaging software 
amira™ at the most superior-posterior edge of the Commissura anterior, we were able to 
reach a reference-associated segmentation of the cingulate gyrus in an anterior and a 
posterior part (Figure 1). 
 
For a standard definition of the subdivision of the ACC, a line, defined by the coronal plane 
passing through the most anterior tip of the inner surface of the genu of the corpus callosum, 
was used as the border between the RACC and the CACC on one hand.  A different line, 
which was set by using the coronal plane passing through the most anterior tip of the outer 
surface of the genu of the corpus callosum, served as border between the RACC and the 
SCC (Figure 1 and 2). This was described before by Crespo-Facorro et al. (1999) (Crespo-
Facorro et al., 1999). 
 
 
Right Cingulate Cortex: white: right SCC; yellow: right RACC, blue: right CACC; cyan: right PCC 
Figure 2  
 The PCC was bounded by the VCA-line on the one side (as mentioned to be the border 
between ACC and PCC), and by a line, which was found by the coronal plane touching the 
most posterior tip of the outer surface of the splenium of the corpus callosum. This line was 
used to have an equal reference for the dorsal border of the PCC. 
Using the most sagittal plane of each hemisphere and considering the reference lines 
described before, the four ROI’s (both left and right) were marked by with a mouse-driven 
cursor in eight different colours (Figure 1). The paracingulate gyrus was considered to be a 
part of the anterior cingulate gyrus, as assumed commonly and practiced by several studies 
before (Crespo-Facorro et al., 1999; Koo et al., 2008). For an accurate assessment and 
tracing of the gray matter associated to the overall eight different ROI’s, tracing was made in 
a serial of coronal planes starting on the first plane showing marked RACC tissue (defined in 
the sagittal plane before) and was continued caudally. With this strategy, the area defined in 
the sagittal plane was consequently extended in each coronal plane to gain a three-
dimensional information of the cingulate gray matter volume. The deepest point of the 
callosal sulcus and the most medial point of the dorsal bank of the cingulate sulcus were 
used as the inner and the outer boundaries of the ACC and the PCC in each coronal slice. If 
there was a paracingulate gyrus, the next superior sulcus associated to its gray matter was 
used as upper border (Figure 2). 
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